TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01193348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
Study: NCT02988076

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEER Interactive Report
Description: A subinvestigator treating a Treatment Group subject will receive the Psychiatric Electroencephalogram Evaluation Registry (PEER) Interactive Report (of probable medication response) under investigation and will incorporate the Report information during prescription of medications to the Subject. A subinvestigator treating a Control Group subject will NOT receive the PEER Report and will treat the Subject with Standard of Care. The subject will be blinded to group assignment and will provide the primary outcome measure - Quick Inventory of Depressive Symptomatology - Self Report 16 item questionnaire.
Study: NCT03286361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BeGraft Peripheral Plus Stent Graft System
Description: Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
Study: NCT04471727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6070
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ifinatamab Deruxtecan (I-DXd)
Description: IV infusion
Study: NCT04904549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series)
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: liquid. Route of administration: intramuscular administration.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: liquid. Route of administration: intramuscular administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent D614)(primary series)& SARS-CoV-2 adjuvanted recombinant protein vaccine(monovalent B.1.351)(booster dose)>=4 months after last vaccination
Description: Pharmaceutical form: emulsion for injection. Route of administration: intramuscular injection.
Study: NCT02969564

Intervention type: OTHER
Intervention: scintigraphy 99mTc-MDP-SPECT/CT.
Description: SPECT/CT will be performed for every patient in the frame of their clinical follow up

Intervention type: OTHER
Intervention: 18F-NaF-PET/MR
Description: a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
Study: NCT03526172

Intervention type: PROCEDURE
Intervention: High tibial osteotomy
Description: Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.

Intervention type: PROCEDURE
Intervention: High tibial osteotomy
Description: Uni-lateral medial opening-wedge high tibial osteotomy following a minimally invasive approach.

Intervention type: DEVICE
Intervention: Allograft wedge
Description: Insertion of allograft wedge into the osteotomy gap during the HTO procedure

Intervention type: DEVICE
Intervention: Accelerometer
Description: ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery

Intervention type: DEVICE
Intervention: Accelerometer
Description: ActivPal accelerometer attached to thigh of patient to collect objective physical activity data at pre-determined intervals before and after surgery

Intervention type: OTHER
Intervention: Questionnaire
Description: Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery

Intervention type: OTHER
Intervention: Questionnaire
Description: Validated clinical questionnaires administered to patients to collect subjective physical activity data at pre-determined intervals before and after surgery
Study: NCT01380080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla (r)
Description: Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla (r)
Description: Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants will take one 600 mg tablet administered orally once daily without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Participants will take one 600 mg tablet administered orally once daily without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin/isoniazid/pyrazinamide/ethambutol FDC
Description: Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin/isoniazid FDC
Description: Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: INH 300 mg orally once daily
Study: NCT04581083

Intervention type: DIAGNOSTIC_TEST
Intervention: RT-PCR
Description: RT-PCR (Gold standard): Real-time PCR testing with reverse transcriptase (RT-PCR). The test consists of a polymerase chain reaction that has previously had a reverse transcription phase, RT. This test allows the cADN (complementary DNA) to be obtained from a RNA chain. This technique allows the detection and amplification of a sequence from a strand of RNA.

Intervention type: DIAGNOSTIC_TEST
Intervention: LAMP
Description: LAMP: The LAMP technique, like PCR, has the ability to amplify specific DNA fragments (target sequence), allowing for highly sensitive detection of pathogens. Unlike pcr, LAMP requires between 4 and 6 feeders, external F3 and B3 feeders, which hybridte with the outer regions of the target sequence, while the internal FIP and BIP have sequences in both ways that allow the formation of a loop. The LAMP reaction is isothermal, i.e. it takes place at a single temperature. LAMP has been successfully used to detect viral diseases as well as viral pathogens such as West Nile virus, TMR-1, Norovirus, avian influenza, foot-and-mouth disease, classical swine fever, among others.

Intervention type: DIAGNOSTIC_TEST
Intervention: POOL RT-PCR
Description: POOL RT-PCR: This test aims to mix in a single sample the extractions obtained from several people. The joint sample is evaluated and, if negative, it is understood that all are free of COVID-19; if it is positive, an array system is used to detect the affected person. That is, a single PCR (polymerase chain reaction), the diagnostic test used to detect the virus pathogen is applied to a group and repeated individually if positive.

Intervention type: DIAGNOSTIC_TEST
Intervention: POOL LAMP
Description: POOL LAMP: Like the RT-PCR pool test. This test essentially involves mixing in a single sample the extractions obtained from several people. This joint sample is tested and, if it is negative, it is understood that everyone is free of COVID-19; if it is positive, an array system is used to detect the affected person. That is: a single LAMP applies to a group
Study: NCT02185768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dc- Beads 300-500µm
Study: NCT04499053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: durvalumab 1500 mg, intravenous, every 3 weeks for 4 cycles, followed by 1500 mg, intravenous, every 4 weeks (maintenance treatment)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: tremelimumab 75 mg, intravenous, every 3 weeks for 4 cycles. A dose of tremelimumab 75 mg will be given at week 16.
Study: NCT02599896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB (VRC01LS)
Description: VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB (VRC01LS)
Description: VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB (VRC01LS)
Description: VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB (VRC01LS)
Description: VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB (VRC01LS)
Description: VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB080-00-AB (VRC01LS)
Description: VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB060-00-AB (VRC01)
Description: VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-HIVMAB060-00-AB (VRC01)
Description: VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
Study: NCT03642119

Intervention type: DEVICE
Intervention: iButton®
Description: Women with frequently reported hot flashes will be undergo both real world (ambulatory; field tests) and controlled (laboratory) assessments to validate the iButton® as an objective method to assess hot flash dynamics and incidence.
Study: NCT02262832

Intervention type: DRUG
Group type: OTHER
Intervention: Metreleptin
Description: administered subcutaneously 1-2 times/day
Study: NCT00988559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccination
Description: vaccination with pNGVL4a-CRT/E7(detox)
Study: NCT02197299

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04448717

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Antibody testing
Description: COVID-19 Antibody testing in venous blood and/or saliva samples.

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Antibody testing
Description: COVID-19 Antibody testing in venous blood and/or saliva samples.
Study: NCT00988559

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccination
Description: vaccination with pNGVL4a-CRT/E7(detox)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccination
Description: vaccination with pNGVL4a-CRT/E7(detox)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA vaccination
Description: vaccination with pNGVL4a-CRT/E7(detox)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gene gun vaccine
Description: 8 micrograms (group 1) or 16 micrograms (group 2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intramuscular vaccination
Description: 1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra-lesional vaccine administration
Description: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: intra-lesional vaccine administration
Description: 1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic resection of the lesion
Description: at week 15, all residual lesions will be resected

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic resection of the lesion
Description: at week 15, all residual lesions will be resected
Study: NCT04448717

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Antibody testing
Description: COVID-19 Antibody testing in venous blood and/or saliva samples.
Study: NCT00751036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
Study: NCT03673579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICU Dashboard
Description: The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICU Dashboard
Description: The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
Study: NCT03106350

Intervention type: OTHER
Intervention: Questionnaire
Description: The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
Study: NCT01830231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinflunine
Description: Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:~* 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of~* 280 mg/m2 in patients aged \>75 - ≤80 years or with PS 1 or prior pelvic radiation,~* 250 mg/m2 in patients aged \>80 years.
Study: NCT03468803

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Beta D Glucan test
Description: Measurement of BDG before, during and after surgery
Study: NCT03566862

Intervention type: DIAGNOSTIC_TEST
Intervention: Leicester Cough Monitor (LCM)
Description: The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.

Intervention type: DIAGNOSTIC_TEST
Intervention: Leicester Cough Monitor (LCM)
Description: The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.

Intervention type: DIAGNOSTIC_TEST
Intervention: Leicester Cough Monitor (LCM)
Description: The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.

Intervention type: DIAGNOSTIC_TEST
Intervention: Leicester Cough Monitor (LCM)
Description: The Leicester Monitoring Cough (LCM) kit includes a digital flash voice recorder (Sony ICD-PX333), aA clip-on lapel microphone (Philips LFH9173) and a small carry/travel waist bag.
Study: NCT00988559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic resection of the lesion
Description: at week 15, all residual lesions will be resected

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic resection of the lesion
Description: at week 15, all residual lesions will be resected

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: imiquimod applied to the cervix by the physician
Study: NCT01267097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-Education Program (PEP)
Description: PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
Study: NCT00618683

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardiac Invasive Electrophysiological Study
Description: Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
Study: NCT01913678

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
Study: NCT01267097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-Education Program (PEP)
Description: PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
Study: NCT01913678

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Complete diet
Description: The participants will be given all dietary items in their diet with no additional products.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete diet
Description: The participants will be given all dietary items in their diet with no additional products.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete diet
Description: The participants will be given all dietary items in their diet with no additional products.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole milk
Description: The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.